ALXN1840 for Wilson's Disease
This trial will test a new treatment for Wilson Disease, comparing it to the current standard of care. The trial will last 48 weeks, with an optional 60-month extension period.
- Wilson's Disease
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2018 Phase 2 trial • 29 Patients • NCT02273596
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Could you tell me how many hospitals are testing this procedure?
"In addition to Children's Hospital of Philadelphia in Los Angeles, California, Texas Children's Hospital in Philadelphia, Pennsylvania, and Yale University School of Medicine in Nashville, Tennessee, this study is also enrolling at 20 other locations."
Could you please elaborate on the safety of ALXN1840 for human patients?
"There is enough evidence from prior clinical trials to give ALXN1840 a score of 3 for safety."